Oncology

With advancements happening at unprecedented rates, these are the cell and gene therapy companies and pipelines we’re keeping a close eye on.

The clinical-stage biotech company recently announced the expansion of their phase 1 trial of CYNK-001 in patients with relapsed/refractory acute myeloid leukemia.

Eunice Wang, MD, and Bijal Shah, MD, MS, discussed unmet needs for adult patients with relapsed/refractory ALL and reflect on the current treatment landscape.

Janssen hopes that Vor’s stem cell therapy will allow their bispecific antibody to be better-tolerated.

Bijal Shah, MD, MS, and Eunice Wang, MD, discussed the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy.

Adam Sperling, MD, PhD, from the Dana-Farber Cancer Institute, and an instructor in medicine at Harvard Medical School, discussed managing CAR T-cell therapy–related toxicities in multiple myeloma.

The hematologist from Moffitt Cancer Center discussed the timing of treatment with chimeric antigen receptor T-cell therapy in patients with acute lymphoblastic leukemia.

Bijal Shah, MD, MS, and Eunice Wang, MD, discuss efficacy results of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy for acute lymphocytic leukemia (ALL), and review key safety data.

Eunice Wang, MD, and Bijal Shah, MD, MS, discuss the overall study design and patient population of the ZUMA-3 trial of CAR T-cell therapy in adult patients with R/R ALL.

The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed future directions that ide-cel research may take.

Eunice Wang, MD, and Bijal Shah, MD, MS, discussed the use of MRD status to assess therapeutic response and guide treatment decisions in patients with relapsed/refractory ALL.  

Leo I. Gordon, MD, and others discussed second-line treatment of diffuse large B-cell lymphoma.

Eunice Wang, MD and Bijal Shah, MD, MS, discuss novel agents and emerging therapeutic approaches for the treatment of acute lymphoblastic leukemia.

The director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed overall response rate and stringent complete responses in the CARTITUDE-1 trial.

The director of Mayo Clinic's Lymphoma Program discussed R/R FL and current treatment options.

The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed how the meeting sets the foundation for what’s to come in the treatment of multiple myeloma and other hematologic malignancies.

Genetically modified oncolytic viruses may provide a new strategy against malignant tumors.

The engineered natural killer cells lack the off-target effects of typical CAR T-cell therapy and similarly lack any concerning safety signals.

The director of the Clinical Myeloma Program at NYU Langone Health’s Perlmutter Cancer Center discusses the next steps for CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

The FDA’s designation follows positive data presented at the 2020 ASH meeting.

The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed the phase 2 CARTITUDE-2 trial.

The phase 3 ZUMA-7 trial met both its primary and secondary endpoints.

The professor of medicine and director of the Hematopoietic Stem Cell Transplantation Program at University of Chicago Medicine described the impact of CAR T-cell therapy on the hematologic cancer landscape.

Conversion from MRD positivity to MRD-negative disease in a high-dose patient prompted the expansion of the trial population.

Surveyed oncologists supported the use of CAR T-cell therapy at higher rates than previous years.